Discovery of a highly potent, selective and novel CDK9 inhibitor as an anticancer drug candidate

Article abstract of DOI:10.1016/j.bmcl.2017.06.041

A series of novel hybrid structure derivatives, containing both LEE011 and Cabozantinib pharmacophore, were designed, synthesized and evaluated. Surprisingly, a compound 4d was discovered that highly exhibited effective and selective activity of CDK9 inhi